Clone: 6F2
Background: GFAP (55 kD) is selectively located in astrocytes and represents the major constituent of astrocytic intermediate filaments. GFAP expression levels are highly variable during development of the central nervous system. In adults, GFAP levels increase as a result of the prolifeRation of astrocytes that occurs in a response to a variety of physical, chemical and etiological insults, including Alzheimer’s disease, epilepsy and multiple sclerosis. In the peripheral nervous system GFAP is expressed by Schwann cells. Upon differentiation, myelin forming Schwann cells down-regulate GFAP, whereas in non-myelin forming Schwann cells GFAP persists into adulthood.
Source: 6F2 is a Mouse monoclonal IgG1 antibody derived by fusion of Mouse myeloma cells with spleen cells from a Mouse immunized with glial fibrillary acidic protein from Human brain.
Specificity: 6F2 reacts exclusively with glial fibrillary acidic protein which is present in astrocytes in the central nervous system and Schwann cells.
Formulation: The vial contains 100 ul 1 mg/ml monoclonal purified antibody in PBS containing 0.09% sodium azide.
References: 1. Van Muijen, G. N., Ruiter, D. J., and Warnaar, S. O. (1987). Coexpression of intermediate filament polypeptides in Human fetal and adult tissues, Lab Invest 57, 359-69.
UniProt: P14136
Caution: This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals. This product contains sodium azide. To prevent formation of toxic vapors, do not mix with strong acidic solutions. To prevent formation of potentially explosive metallic azides in metal plumbing, always wash into drain with copious quantities of water.This datasheet is as accurate as reasonably achievable, but Nordic-MUbio accepts no liability for any inaccuracies or omissions in this information.
English
Deutsch
